AUA
  • Program
  • Register
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
  • Photo Gallery
Topics
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
  • Photo Gallery
Resources
  • Program
  • Register
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
Sep 15, 2021

Guideline updates

Taking aim at best practices.


Tips And Tricks

AUA2021 featured a number of sessions highlighting updated guidelines or outlining new guidelines in the specialty of urology.

A new guideline published in January 2021 combines and updates two earlier guidelines on follow-up for clinically localized renal neoplasms (2013) and on evaluation and management of renal masses and localized renal cancer (2017). Four of the recent guideline authors discussed the updated guideline during the session “Evaluation and Management of Localized Renal Masses: A Case-Based Approach.”

AUA’s new Advanced Prostate Cancer Guidelines were outlined during the session “AUA Guidelines: Advanced Prostate Cancer,” which provided an overview of Parts I and II of the two-part guideline series dedicated to advanced prostate cancer treatment. The session served as a preview to the session “AUA Guidelines on Advanced/Metastatic/Castration-Resistant Prostate Cancer.”

Last week’s instructional course “Refractory Overactive Bladder: How to Select Third-Line Therapies and Optimize Outcomes” described the new 2019 American Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction guideline provides first-, second- and third-line evidence-based treatment approaches for the diagnosis and treatment of non-neurogenic overactive bladder.

The guideline on non-muscle invasive bladder cancer from the AUA and the Society of Urologic Oncology, which was published in 2016, was amended and updated in 2020. The newest version includes new treatment options and proven strategies when Bacillus Calmette-Guérin is scarce. These updates were outlined in the session “Guidelines and Beyond: Case-Based Approach to Non-Muscle Invasive Bladder Cancer.”

Visit AUA2021 Daily News Online for more articles.

Interesting Stories
YONSA® (abiraterone acetate) Holds a Full House of Benefits—See Booth 1222
Sponsored by Sun Pharma
YONSA® (abiraterone acetate) Holds a Full House of Benefits—See Booth 1222
Book your AUA2025 housing now
Sponsored by AUA
Book your AUA2025 housing now
Register for the Career Fair at AUA2025
Sponsored by AUA
Register for the Career Fair at AUA2025
More Content
Getty Images 1208851295
AUA2022
Save the date
Jan 31, 2022
Aua Wrap 04
AUA2021
AUA2021 On Demand: see what’s streaming
Sep 22, 2021
Aua Wrap 03
AUA2021
Satellite symposia bring expert insights
Sep 22, 2021
Aua Wrap 01
AUA2021
Education and training for young urologists
Sep 22, 2021
Getty Images 1199215126
AUA2021
Claim your CME
Sep 22, 2021
Aua Wrap 05
AUA2021
Read all about it
Sep 22, 2021
Aua Tv
AUA2021
Must-see TV
Sep 22, 2021
Getty Images 185224486
AUA2021
AUA2021: By the numbers
Sep 15, 2021
Toni K. Choueiri, MD
AUA2021
Late-breaking science
Sep 15, 2021
Ian M. Thompson Jr., MD
AUA2021
Award winners
Sep 15, 2021
Ai
AUA2021
New technology
Sep 15, 2021
Use Sexual Medicine
AUA2021
Panel discussions
Sep 15, 2021
AUA
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
© 2025 Ascend Media. All rights reserved.